Harpreet S. Dhaliwal - 05 Aug 2026 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Reporting relationship: Chief Technical Ops Officer
Issuer ticker: PCVX
Reported as of: 05 Aug 2026
Net transaction value: -$935,068
SEC form: 4
Accepted by SEC: 05 Aug 2026, 19:01:41 UTC
Prior SEC filing: 11 Mar 2026
Next SEC filing: 02 Sep 2026
Source filing: View source filing
Reporting owner signature: Harpreet S. Dhaliwal, by /s/ Peter N. Efremenko, Attorney-In-Fact

Key filing fact

Harpreet S. Dhaliwal filed Form 4 for Vaxcyte, Inc. (PCVX) on 05 Aug 2026.

Key facts

This page summarizes Harpreet S. Dhaliwal's Form 4 filing for Vaxcyte, Inc. (PCVX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Aug 2026, 19:01.

Change

Previous filing in this sequence was filed on 11 Mar 2026.
Current net transaction value: -$935,068.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001886794 Primary reporting owner

Dhaliwal Harpreet S.

Relationship: Chief Technical Ops Officer
Address: C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS
Signature: Harpreet S. Dhaliwal, by /s/ Peter N. Efremenko, Attorney-In-Fact
Signature date: 05 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PCVX transaction

Common Stock

Options Exercise

Transaction value
Shares: +17,000
Change %: +22%
Price: $24.79^*
Shares after: 93,756
Date: 05 Aug 2026
Ownership: Direct
Footnotes: F1

PCVX transaction

Common Stock

Sale

Transaction value: $935,068
Shares: -17,000
Change %: -18%
Price: $55.00
Shares after: 76,756
Date: 05 Aug 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCVX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -17,000
Change %: -38%
Price: $0.000000^*
Shares after: 28,000
Date: 05 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,000
Exercise price: $24.79
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Includes 780 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026.

Footnote F2

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 6, 2026.

Footnote F3

The price reported is a weighted-average price. The shares were sold at prices ranging from $55.00 to $55.255. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F4

Stock Option is fully vested and exercisable.